Skip to content
BiologicalX

Comparison

Alpha-Lipoic Acid vs Magnesium Glycinate

Side-by-side of Alpha-Lipoic Acid and Magnesium Glycinate. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Alpha-Lipoic Acid

  • Approved Rx for diabetic neuropathy in Germany at 600 mg/day IV (Thioctacid) since 1960s
  • Improves neuropathy symptoms (TSS, NIS) at 600 mg/day IV across ALADIN and SYDNEY trials
  • R-ALA enantiomer absorbs 40-100% better than racemic mixtures
  • Activates AMPK; produces small HbA1c reductions in T2DM
  • Plasma half-life ~30 minutes; split dosing or sustained-release is standard
  • Hypoglycemia risk with insulin or sulfonylureas; medication adjustment may be required

Magnesium Glycinate

  • Shortens sleep onset latency in older adults and in deficient populations supplementing 200 to 400 mg elemental Mg
  • Improves subjective sleep quality scores (PSQI, ISI) modestly versus placebo over 4 to 8 weeks
  • Reduces nocturnal leg cramps and exercise-induced muscle cramping in some controlled trials
  • Lowers self-reported anxiety in mild-to-moderate cases, with smaller effect than first-line pharmacotherapy
  • Glycinate form delivers fewer GI side effects than oxide or citrate at equivalent elemental doses
  • Insufficient as a stand-alone hypertension treatment; small adjunctive blood-pressure reductions only

Side-by-side

Attribute Alpha-Lipoic Acid Magnesium Glycinate
Category supplement supplement
Also known as ALA, thioctic acid, R-ALA, R-lipoic acid magnesium bisglycinate
Half-life (hr) 0.5 5
Typical dose (mg) 600 300
Dosing frequency 1 to 3 times daily on empty stomach daily (often evening)
Routes oral, iv oral
Onset (hr) 0.5 1
Peak (hr) 1 -
Molecular weight 206.33 -
Molecular formula C8H14O2S2 -
Mechanism Dual lipid- and water-soluble antioxidant; redox cycles with dihydrolipoic acid (DHLA) to scavenge ROS, regenerate vitamin E and C, and chelate transition metals. Activates AMPK in liver and muscle; cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes. Magnesium acts as a cofactor for 300+ enzymes and as a voltage-dependent antagonist at NMDA receptors; glycine serves as an inhibitory neurotransmitter and co-agonist at glycine receptors.
Legal status Dietary supplement (US, UK, Canada, most EU); prescription drug for diabetic neuropathy in Germany Dietary supplement
WADA status allowed allowed
DEA / Rx Not scheduled OTC supplement
Pregnancy Insufficient data; precautionary avoidance Generally considered acceptable at RDA doses; consult clinician
CAS 62-46-4 14783-68-7
PubChem CID 864 84645
Wikidata Q161227 -

Safety profile

Alpha-Lipoic Acid

Common side effects

  • nausea
  • abdominal discomfort
  • diarrhea
  • sulfurous odor
  • rash (rare)

Contraindications

  • pregnancy and lactation (insufficient safety data)
  • active insulin autoimmune syndrome predisposition

Interactions

  • insulin and sulfonylureas: additive hypoglycemia; medication dose adjustment may be required(major)
  • thyroid hormone: may reduce T4 to T3 conversion at high doses(moderate)
  • biotin: ALA competes with biotin uptake; chronic use can induce biotin insufficiency(minor)
  • iron supplements: ALA chelates iron and reduces absorption; separate dosing(moderate)
  • chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)

Magnesium Glycinate

Common side effects

  • mild GI upset at high doses
  • loose stools (dose-dependent, less than with oxide/citrate forms)

Contraindications

  • severe renal impairment
  • myasthenia gravis
  • heart block

Interactions

  • tetracycline and fluoroquinolone antibiotics: magnesium chelates antibiotic, reducing absorption; separate by 2+ hours(moderate)
  • bisphosphonates: reduced absorption of bisphosphonate(moderate)
  • potassium-sparing diuretics: possible hypermagnesemia in renal impairment(moderate)

Which Should You Take?

Magnesium Glycinate comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Alpha-Lipoic Acid is the right call when one of the conditionals below applies.

Edge case: Half-lives differ materially (Alpha-Lipoic Acid ~0.5 hr vs Magnesium Glycinate ~5 hr). Magnesium Glycinate reaches steady state faster; Alpha-Lipoic Acid is easier to dial in if tolerability is uncertain.

Default choice: Magnesium Glycinate. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Alpha-Lipoic Acid only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Alpha-Lipoic Acid and Magnesium Glycinate?

Alpha-Lipoic Acid and Magnesium Glycinate differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Alpha-Lipoic Acid or Magnesium Glycinate?

Alpha-Lipoic Acid half-life is 0.5 hours; Magnesium Glycinate half-life is 5 hours.

Can you stack Alpha-Lipoic Acid with Magnesium Glycinate?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper